APAC

Asia Pacific equity research

Explore the most viewed and latest equity research and media content we have for listed companies based in the Asia-Pacific region.

APAC Equity Research

Broker research, valuations, and analysis on Asia-Pacific stocks

20 Feb 19

Bitesize briefing - Alkane Resources

09 Mar 17

Executive interview - Imugene

29 Sep 16

Executive Interview - Leaf Resources

06 Jul 16

YPB technology - John Houston

09 Nov 18

Executive interview - ERM Power

05 Jun 16

Bennelong Kardinia Absolute Return Fund performance update

14 Jun 16

Talking Stock: Peak Asset Management’s Niv Dagan comments on markets and opportunities

22 May 16

(ASX:YPB) – Placement at 18.6% discount to Friday’s closing price at $0.24

17 Jun 16

Talking Stock: Peak Asset Management’s Niv Dagan comments on markets and opportunities

19 May 16

Talking Stock: Peak Asset Management’s Niv Dagan comments on markets and opportunities

09 Jun 16

Minotaur RAMPS UP FIELD ACTIVITY in June

01 May 16

Minotaur identifies new targets near Prominent Hill

03 Dec 15

Fund aims to provide outperformance with lower fees

27 Apr 16

Northern Star's March 2016 Quarter Results

13 Jul 15

Executive Interview - Cooks Global Foods

Latest Content

Actinogen Medical

Actinogen Medical - Differentiated treatment for Alzheimer’s disease

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem® is a selective 11β-HSD1 inhibitor that is able to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in Alzheimer's disease (AD). The ongoing Phase II XanADu trial is fully enrolled with mild AD patients, who receive Xanamem in conjunction with standard of care. The results are due by end-Q219 and will shape further development of Xanamem. Our valuation is A$195m or A$0.17/share.

View

18 Mar 19
-
-

Telix Pharmaceutical

Updated PCa imaging guidelines de-risk lead asset

Telix Pharmaceuticals today announced the inclusion of PSMA-PET in the European Association of Urology's ("EAU") clinical guidance for the management of prostate cancer in patients with suspected recurrent disease, which should provide a significant boost to Telix’s illumet (68Ga PSMA-11) PSMA-PET imaging agent. Already used as a companion diagnostic in Endocyte’s ongoing pivotal prostate cancer Phase III trial and the subject of a distribution deal with Cardinal Health in the US, inclusion of PSMA-PET should facilitate both regulatory approval and adoption of 68Ga PSMA-11 in Europe. Telix’s own Phase III-ready radiopharmaceutical TLX-591 shows better efficacy and tolerability compared to Endocyte's 177Lu-PSMA-617. With renal cancer and glioma programmes progressing, Telix looks undervalued, in our view. We reiterate both our OUTPERFORM recommendation and AUD 2.50 target price.

View

18 Mar 19
-
-

Prada

Momentum slowed in H2

Sales momentum slowed in H2 and closed the year up 6% at local currency. Trading conditions were tough in Hong Kong and Macau. Fewer tourists in Europe and America have deepened the slow down. Margins were much lower than expected.

View

15 Mar 19
-
-

UNITED CO RUSAL

Overall stable operating results, even after a gruelling year

Rusal ended 2018 on a steady note, despite the various (market) difficulties – whose impact was pertinently visible in the Q4 performance. For the full-year, euphoric (price) gains in Alumina largely compensated for Aluminium’s weakness. Moreover, Norilsk Nickel remained a prized support. With the US sanctions now being removed, normal business operations should be restored from 2019 onwards. Further support is likely to surface via expected global (ex. China) market deficits.

View

08 Mar 19
-
-

ABM ASO BEM CON LRA ORR RMM TLG

SP Angel – Morning View

African Battery Metals (ABM LN) – Reborn | Avesoro Resources (ASO LN) – New Liberty underground mining pre-feasibility study | Beowulf Mining* (BEM LN) – Swedish investors continue to buy Beowulf Mining shares | Connemara Mining* (CON LN) – Directors and existing shareholders subscribe £230,000 | Lara Exploration (LRA CN) – CAD$2.0m private placing | Oriole Resources (ORR LN) – Gold mineralisation confirmed in trenching at Bibemi | Rambler Metals (RMM LN) – Appointment of CFO | Talga Resources (TLG AU) – Graphene-infused concrete Innovation Award nomination

View

07 Mar 19
-
-

MGC Pharmaceuticals

MGC Pharmaceuticals - MGC Derma sale completed

Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contracts for the construction of a cannabis production and cultivation facility in Malta, and initiation of a Phase II study of CogniCann in dementia. The company has completed the sale of MGC Derma to CannaGlobal, which was announced in September. The transaction was restructured in November, which sees us reduce our valuation of the consideration to A$7.5m (vs A$12.5m). We adjust our valuation to A$135m (vs A$140m) due to the lower transaction valuation.

View

04 Mar 19
-
-

CMCL HUM ORR RMM RIO SAV SRB SML VAST VALE

SP Angel – Morning View

Caledonia Mining (CMCL LN) – Withdrawal of ECI scheme for gold producers | Hummingbird Resources (HUM LN) – Yanfolila exploration update | Oriole Resources (ORR LN) – Dalafin exploration to resume next month | Rambler Metals (RMM LN) – Private placement raises US$11m | Rio Tinto (RIO LN) – Iron ore mineral resource update | Savannah Resources* (SAV LN) – Significant new high-grade lithium discovery | Serabi Gold (SRB LN) – Mineral resource update for Coringa | Strategic Minerals* (SML LN) – Final shares issued for the Leigh Creek acquisition | Vale – Vale CEO and other executives resign following pressure from prosecutors | Vast Resources (VAST LN) – c.£850 equity placing

View

04 Mar 19
-
-

Alkane Resources

Alkane Resources - Profit after tax decreases by 10% y-o-y

Gold mining operations at Tomingley performed strongly, with Alkane Resources reporting profit after tax of A$12.2m in H119 (the half year to December 2018) on the back of production of 26,754oz of gold. The 10% decline in net profit from A$13.5m in H118, along with lower production volumes and grades, was expected, reflecting the cessation of open pit mining in January 2019 as Alkane transitions underground. Development of the underground operation at Tomingley is progressing on schedule, with both the main decline and vent portals established. During H219, we expect gold production volumes, c 13,000oz, and grades to continue to decline as Alkane will be processing the mid-grade stockpile until ore from underground is extracted at some point in H219.

View

01 Mar 19
-
-

ERM Power

ERM Power - 30% dividend hike a strong positive signal

At its H119 results, ERM Power sent a strong positive signal about the outlook for its Electricity Retail business, upgrading its medium-term gross margins per unit by c 10%. The c 30% dividend hike, the additional 3c/share special dividend and A$60m reserved for investments in growth also show the balance sheet and the cash flow are strong.

View

01 Mar 19
-
-

SARINE TECHNOLOGIES

Sarine Technologies - External factors remain challenging

Sarine continued to experience more muted midstream demand in Q418, both in terms of capital equipment sales and recurring revenues. At the same time, it has kept its operating expenses under control, which allowed it to post a 6.3% y-o-y improvement in operating profit in FY18. As sales and marketing initiatives intensify in 2019 while industry challenges persist, the company has decided to temporarily reduce its dividend policy to one US cent every six months (from 2 US cents before), which still translates into a solid dividend yield at c 5% on an annualised basis.

View